ALRN Logo

Aileron Therapeutics, Inc. (ALRN) 

NASDAQ
Market Cap
$56.31M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
323 of 774
Rank in Industry
191 of 432

Largest Insider Buys in Sector

ALRN Stock Price History Chart

ALRN Stock Performance

About Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in …

Insider Activity of Aileron Therapeutics, Inc.

Over the last 12 months, insiders at Aileron Therapeutics, Inc. have bought $758 and sold $281,909 worth of Aileron Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aileron Therapeutics, Inc. have bought $3.56M and sold $281,909 worth of stock each year.

Highest buying activity among insiders over the last 12 months: WINDSOR JAMES BRIAN (President and COO) — $1,517.

The last purchase of 225 shares for transaction amount of $758 was made by WINDSOR JAMES BRIAN (President and COO) on 2023‑12‑15.

List of Insider Buy and Sell Transactions, Aileron Therapeutics, Inc.

2024-06-17Sale10 percent owner
4,707
0.0219%
$3.25$15,298-9.35%
2024-06-14Sale10 percent owner
1,900
0.009%
$3.30$6,270-9.63%
2024-06-12Sale10 percent owner
9,342
0.0435%
$3.25$30,362-8.00%
2024-06-11Sale10 percent owner
5,752
0.0269%
$3.26$18,744-7.28%
2024-06-10Sale10 percent owner
9,577
0.046%
$3.30$31,604-5.66%
2024-06-07Sale10 percent owner
1,740
0.0081%
$3.26$5,664-6.79%
2024-06-06Sale10 percent owner
4,284
0.0199%
$3.29$14,104-7.60%
2024-06-05Sale10 percent owner
6,291
0.0291%
$3.30$20,760-7.27%
2024-05-01Sale10 percent owner
20,315
0.1211%
$4.21$85,473-22.12%
2024-04-30Sale10 percent owner
90
0.0006%
$4.97$448-28.79%
2024-04-29Sale10 percent owner
10,746
0.0637%
$4.95$53,182-34.04%
2023-12-15PurchasePresident and COO
225
0.0043%
$3.37$758+5.07%
2023-11-20PurchasePresident and COO
5,076
0.1087%
$1.97$9,987+92.04%
2021-01-08PurchaseSee Remarks
9M
8.7946%
$1.10$9.9M-14.81%
2020-06-15Purchasedirector
5,800
0.0189%
$1.22$7,076+2.50%
2020-06-08Purchase
3.7M
11.0475%
$1.10$4.07M+4.24%
2020-06-08Purchasedirector
227,272
0.6786%
$1.10$249,999+4.24%
2019-11-15Purchasedirector
39,142
0.1624%
$0.51$19,962+60.68%
2019-11-14Purchasedirector
15,858
0.0646%
$0.51$8,088+57.84%
2019-11-12Purchasedirector
19,894
0.0805%
$0.53$10,544+50.37%

Insider Historical Profitability

<0.0001%
WINDSOR JAMES BRIANPresident and COO
225
0.001%
$2.6020
Satter Muneer ASee Remarks
16609449
76.6617%
$2.6030<0.0001%
Novartis Bioventures Ltd10 percent owner
2079394
9.5975%
$2.60127<0.0001%
Gallagher Brian M. Jr.director
1431519
6.6072%
$2.6010<0.0001%
Shanafelt Armendirector
1094987
5.054%
$2.6010<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.